<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4435">
  <stage>Registered</stage>
  <submitdate>8/05/2014</submitdate>
  <approvaldate>8/05/2014</approvaldate>
  <nctid>NCT02135536</nctid>
  <trial_identification>
    <studytitle>Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis</studytitle>
    <scientifictitle>A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>14-0104</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary Biliary Cirrhosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - NGM282

Experimental: NGM282 Dose 1 - NGM282 Dose 1

Experimental: NGM282 Dose 2 - NGM282 Dose 2

Experimental: NGM282 Dose 3 - NGM282 Dose 3


Other interventions: NGM282
NGM282

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change in plasma ALP from Baseline to Week 12</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change in bilirubin, ALT, AST, and GGT from Baseline to Week 12 and Week 24</outcome>
      <timepoint>12 weeks and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Completion of NGM 13-0103

          -  Males or females, between 18 and 75 years of age, inclusive

          -  PBC Diagnosis consistent with AASLD and EASL guidelines

          -  Stable dose of UDCA</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Chronic liver disease of a non-PBC etiology

          -  Evidence of clinically significant hepatic decompensation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>NGM Clinical Study Site 602 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 606 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 609 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 611 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 614 - Brisbane</hospital>
    <hospital>NGM Clinical Study Site 607 - Adelaide</hospital>
    <hospital>NGM Clinical Study Site 608 - Adelaide</hospital>
    <hospital>NGM Clinical Study Site 601 - Melbourne</hospital>
    <hospital>NGM Clinical Study Site 613 - Melbourne</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>NGM Biopharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>NGM Biopharmaceuticals Australia Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability, and activity of extended
      treatment with NGM282 in patients with Primary Biliary Cirrhosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02135536</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen J Rossi, PharmD</name>
      <address>NGM Biopharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>